Fucose

L-Fucose

Names
IUPAC name 6-Deoxy-L-galactopyranose
Systematic IUPAC name (2S,3R,4R,5S)-6-Methyltetrahydro-2H-pyran-2,3,4,5-tetraol
Other names 6-Deoxy-L-galactose
Identifiers
CAS Number	2438-80-4 Y
3D model (JSmol)	Interactive image
ChEBI	CHEBI:2181 Y
ChEMBL	ChEMBL469449 Y
ChemSpider	16190 Y
PubChem CID	17106
UNII	28RYY2IV3F Y
InChI InChI=1S/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1 Y Key: SHZGCJCMOBCMKK-DHVFOXMCSA-N Y InChI=1/C6H12O5/c1-2-3(7)4(8)5(9)6(10)11-2/h2-10H,1H3/t2-,3+,4+,5-,6?/m0/s1 Key: SHZGCJCMOBCMKK-DHVFOXMCBB
SMILES O[C@@H]1[C@H](O)[C@@H](OC(O)[C@H]1O)C
Properties
Chemical formula	C6H12O5
Molar mass	164.16 g/mol
Supplementary data page
Fucose (data page)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is YN ?) Infobox references

Fucose is a hexose deoxy sugar with the chemical formula C₆H₁₂O₅. It is found on N-linked glycans on the mammalian, insect and plant cell surface. Fucose is the fundamental sub-unit of the seaweed polysaccharide fucoidan.^[1] The α(1→3) linked core of fucoidan is a suspected carbohydrate antigen for IgE-mediated allergy.^[2]

Two structural features distinguish fucose from other six-carbon sugars present in mammals: the lack of a hydroxyl group on the carbon at the 6-position (C-6) (thereby making it a deoxy sugar) and the L-configuration. It is equivalent to 6-deoxy-L-galactose.

In the fucose-containing glycan structures, fucosylated glycans, fucose can exist as a terminal modification or serve as an attachment point for adding other sugars.^[3] In human N-linked glycans, fucose is most commonly linked α-1,6 to the reducing terminal β-N-acetylglucosamine. However, fucose at the non-reducing termini linked α-1,2 to galactose forms the H antigen, the substructure of the A and B blood group antigens.

Fucose is released from fucose-containing polymers by an enzyme called α-fucosidase found in lysosomes.

L-Fucose has several potential applications in cosmetics, pharmaceuticals, and dietary supplements^[4][5]

Fucosylation of antibodies has been established to reduce binding to the Fc receptor of Natural Killer cells and thereby reduce antibody-dependent cellular cytotoxicity. Therefore, afucosylated monoclonal antibodies have been designed to recruit the immune system to cancers cells have been manufactured in cell lines deficient in the enzyme for core fucosylation (FUT8), thereby enhancing the in vivo cell killing.^[6][7]